Lung screening improves odds for lung cancer survival. Learn who should be screened.
News: November, 2017
Radiation-induced pulmonary fibrosis — tissue scarring that can permanently impair lung function — limits the delivery of therapeutic radiation doses to non-small cell lung cancer. To develop strategies for preventing or reducing fibrosis, Michael Freeman, Ph.D., and colleagues are exploring the cell types and factors that contribute to the radiation-induced fibrotic response.
A simple blood test is allowing Vanderbilt University Medical Center (VUMC) researchers to determine which patients should be prescribed varenicline (Chantix) to stop smoking and which patients could do just as well, and avoid side effects, by using a nicotine patch.
The Vanderbilt-Ingram Cancer Center Neurofibromatosis (NF) Clinic has joined the Children’s Tumor Foundation NF Clinic Network. The network consists of 50 clinics dedicated to improving care and advancing research for people diagnosed with NF, a group of diseases that is often inherited and cause benign tumors to grow on nerves throughout the body.
Vanderbilt University School of Nursing (VUSN) Assistant Professor Bethany Rhoten, Ph.D., MSN, R.N., has been awarded a $30,000 grant through a Vanderbilt-Ingram Cancer Center-administered American Cancer Society pilot program to investigate the need for a self-report tool to assess sexuality in head and neck cancer patients.
Artist Rhonda Jennette, second from right, donated animal-themed art for display in the Radiation Oncology department. Shown here with Jennette are, from left, Mark Stavas, M.D., Leslie Mader, R.N., OCN, and Eric Shinohara, M.D., MSCI. (photo by Susan Urmy)
Amanda Mathis went from being a patient at Vanderbilt-Ingram Cancer Center to becoming a member of the cancer center’s Board of Overseers.
Lung cancer survivors and their caregivers are invited to attend a free educational evening at Vanderbilt University Medical Center (VUMC) Thursday, Nov. 16, 5:30 – 8:30 p.m., at the University Club, 2402 Garland Ave.
Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)